6th pilot rapid assessment of WP5 JA2 Strand B on “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”

The purpose of the assessment is to examine the effectiveness and safety of mechanical thrombectomy in adults aged 18 years or older with acute ischaemic stroke in the anterior and/or posterior region. The analysis included CE-marked aspiration/suction devices, and stent and clot retrievers. Final version of the assessment was published in February 2016 Below is […]

4th pilot rapid assessment of WP5 JA2 Strand B on “Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenosis”

The purpose of the assessment is to address the research question whether the use of biodegradable stents for benign refractory or recurrent oesophageal stenosis is more effective and/or safer than self-expanding metal or plastic stents or oesophageal dilation. Final version of the assessment was published in May 2015 Below is the documentation provided by the […]

3rd Pilot rapid assessment on ‘Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction’

The purpose of the assessment is to evaluate the use of Balloon Eustachian Tuboplasty (BET) for Eustachian tube dysfunction (ETD) in a population aged over 12 years. Final version of the assessment was published in February 2015 Below is the documentation provided by the Joint Assessment authoring team: BET_Project_Plan_3rd pilot_final Comments tables_BET Balloon Eustachian Tuboplasty […]

Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer. Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA-4_RAMUCIRUMAB for the treatment of gastric cancer_APPENDIX_6_INCLUDED Ramucirumab for the treatment of gastric cancer_Rapid […]

Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine

The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team:   Sorafenib for the treatment of thyroid carcinoma_Rapid REA_Final_Mar 2015_0